Compound: Terramycin
SMILES: O=C1c2c(O)cccc2[C@](O)(C)[C@@H]3C1=C(O)[C@]4(O)C(=O)C(=C(O)[C@H]([C@@H]4[C@H]3O)N(C)C)C(=O)N
InChIKey: IWVCMVBTMGNXQD-PXOLEDIWSA-N
Synonyms: Terramycin, RefChem:932744, Lidocaine hydrochloride; oxytetracycline, (4S,4aR,5S,5aR,6S,12aR)-2-carbamoyl-4-(dimethylazaniumyl)-5,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracen-1-olate, 103-115-5, oxytetracycline, 79-57-2, Oxymycin, Oxitetraciclina, Oxytetracyclin, Oxyterracine, Ryomycin, Biostat, Oxitetracyclin, Terramitsin, Adamycin, Riomitsin, Oxytetracycline (anhydrous), Tetran, Oxitetracyclinum, Oxytetracyclinum, Oxyterracin, Oxytetracycline anhydrous, Terrafungine, 5-Hydroxytetracycline, Oxyterracyne, Solkaciclina, Dabicycline, Fanterrin, Geomycin, Geotilin, Imperacin, Lenocycline, Oksisyklin, Proteroxyna, Ursocyclin, Ursocycline, Oxypam, Tarocyn, Tarosin, Teravit, Antibiotic TM 25, Oxytetracycline amphoteric, Liquamycin LA 200, Biostat PA, Oxytetracycline [INN], Berkmycen, Oxysteclin, Oxymykoin, Vendarcin, Ossitetraciclina, Pennox 200, Oxy-Kesso-tetra, Oxytetracycline (Terramycin), Stevacin, Mycoshield TMQTHC 20, Bisolvomycin, Dalimycin, Oxacycline, Unimycin, NSC-9169, Macocyn, Medamycin, Oxytetracycline calcium, Biosolvomycin, Mepatar, OTC (antibiotic), (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, Stecsolin, Oxydon, MLS000069429, NSC 9169, SLF0D9077S, C22H24N2O9, DTXSID1034260, Tetracycline, 5-hydroxy-, Terramycine, Nitox, Oxytetracycline (internal use), MFCD00003700, TM 5, 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6S,12aS)-, Oxytetracid, E703, NCI-C56473, SMR000059000, Terramycin im, Terramycin Q50, Oxytetracycline base, Galsenomycin, Oxytetracycline (dihydrate), Ossitetraciclina [DCIT], (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide, 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, OTC, Oxytetracyclinum [INN-Latin], Oxitetraciclina [INN-Spanish], Terramicina Oftalmica, Geomycin (Streptomyces vimosus), HSDB 3145, NSC-757262, EINECS 201-212-8, LA 200, BRN 2714587, UNII-SLF0D9077S, Embryostat, SR-01000003006, Hydroxytetracyclinum, Oxytetracycline CRS, 5-Hydroxy-Tetracycline, Spectrum_001055, Opera_ID_661, Oxytetracycline dehydrate, Oxytetracyclinum dihydras, Prestwick0_000307, Prestwick1_000307, Prestwick2_000307, Prestwick3_000307, Spectrum2_000988, Spectrum3_000536, Spectrum4_000466, Spectrum5_001148, Doxycycline EP Impurity E, Oxytetracycline (Standard), SCHEMBL2899, CHEMBL1517, OXYTETRACYCLINE [MI], BSPBio_000274, BSPBio_002151, DOXYCYCLINE IMPURITY E, KBioGR_000912, KBioSS_001535, 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6beta,12aalpha))-, 4-14-00-02633 (Beilstein Handbook Reference), DivK1c_000225, SCHEMBL560497, SPBio_001055, SPBio_002493, BPBio1_000302, CHEMBL461529, orb1310191, CHEMBL1401333, CHEMBL4280957, DTXCID9014260, NSC9169 (HCL), OXYTETRACYCLINE [WHO-DD], SCHEMBL13169109, SCHEMBL13782651, SCHEMBL26627996, SCHEMBL29538576, SCHEMBL29876138, CHEBI:27701, GTPL10919, HY-B0275R, KBio1_000225, KBio2_001535, KBio2_004103, KBio2_006671, KBio3_001651, 6153-64-6 (di-hydrate), MSK4111, NINDS_000225, BDBM241973, DTXSID201370921, GLXC-23416, 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, 79-57-2 (ANHYDROUS), HY-B0275, 2058-46-0 (mono-hydrochloride), Tox21_302380, EBC-11061, LMPK07000005, s1773, AKOS015951277, AKOS015961254, CCG-269334, DB00595, FO31724, CAS-79-57-2, IDI1_000225, NCGC00091268-04, NCGC00091268-05, NCGC00091268-06, NCGC00091268-07, NCGC00091268-08, NCGC00091268-09, NCGC00091268-10, NCGC00091268-11, NCGC00091268-12, NCGC00188956-01, NCGC00255168-01, (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione, AC-12777, AC-13466, PD132319, 7179-50-2 (calcium (1:1) salt), OXYTETRACYCLINE (ANHYDROUS) [HSDB], SBI-0051473.P003, NS00000179, ST50307307, SW196796-3, 15251-48-6, Oxytetracycline 100 microg/mL in Acetonitrile, C06624, E75911, Oxytetra Selective Supplement, for microbiology, Oxytetracycline 1000 microg/mL in Acetonitrile, Partially skimmed milk powder - Oxytetracycline, AB00053514_04, AB00053514_05, AB01274728-01, AB01274728_02, 6153-65-7 (di-hydrochloride salt, di-hydrate), Oxytetracycline; Doxycycline Hyclate EP Impurity E, Q411646, DOXYCYCLINE HYCLATE IMPURITY E [EP IMPURITY], SR-01000003006-5, Q63393012, DOXYCYCLINE MONOHYDRATE IMPURITY E [EP IMPURITY], Z1515385075, Oxytetracycline, British Pharmacopoeia (BP) Reference Standard, (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide, (4S,4AR,5S,5AR,6S,12AS)-4-(DIMETHYLAMINO)-3,5,6,10,12,12AHEXAHYDROXY-6-METHYL-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE, (4S,5S,6S,12aS,4aR,5aR)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl -1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide, 2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione, oxypam; macocyn; adamycin; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
Theoretical properties:
molecular_formula: C22H24N2O9
molecular_weight: 460.4 g/mol
exact_mass: 460.14818035 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 7
hydrogen_bond_acceptor_count: 10
rotatable_bond_count: 2
heavy_atom_count: 33
topological_polar_surface_area: 202 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 47 [ug/mL] (The mean of the results at pH 7.4)
Descriptions:
{"pubchem": "Oxytetracycline (internal use) can cause developmental toxicity according to state or federal government labeling requirements.", "chebi": "A zwitterion obtained by transfer of a proton from the 2-hydroxy group to the adjacent tertiary amino group of oxytetracycline; major species at pH 7.3.", "chembl": "OXYTETRACYCLINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Oxytetracycline is a broad-spectrum tetracycline antibiotic, the second of the group to be discovered.\nOxytetracycline works by interfering with the ability of bacteria to produce essential proteins. Without these proteins, the bacteria cannot grow, multiply and increase in numbers. Oxytetracycline therefore stops the spread of the infection, and the remaining bacteria are killed by the immune system or eventually die.\nOxytetracycline is active against a wide variety of bacteria. However, some strains of bacteria have developed resistance to this antibiotic, which has reduced its effectiveness for treating some types of infections.\nOxytetracycline is used to treat infections caused by Chlamydia, such as psittacosis, trachoma, and urethritis, and infections caused by Mycoplasma organisms, such as pneumonia.\nOxytetracycline is used to treat acne, due to its activity against the bacteria on the skin that influence the development of acne (Cutibacterium acnes). It is used to treat flare-ups of chronic bronchitis, due to its activity against Haemophilus influenzae. Oxytetracycline may be used to treat other rarer infections, such as those caused by a group of microorganisms called rickettsiae (e.g., Rocky Mountain spotted fever). To make sure the bacteria causing an infection are susceptible to it, a tissue sample is usually taken; for example, a swab from the infected area or a urine or blood sample.\nOxytetracycline was patented in 1949 and came into commercial use in 1950. It is on the World Health Organization's List of Essential Medicines as an alternative to tetracycline.\n\n"}